Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Certain problems of therapy with beta-interferon preparations].

E I Gusev, T L Demina, A N Boĭko

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |August 27, 2003
    PubMed
    Summary

    Beta-interferon-1b (betaferon) shows moderate side effects and is effective for multiple sclerosis (MS) treatment. Neutralizing antibodies (NAB) do not significantly impact its positive clinical effects, supporting its role as a foundational therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Results of the implementation of reperfusion technologies in ischemic stroke].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
    Same author

    [Clinical guidelines «Cognitive disorders in the elderly and senile persons»].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025

    Area of Science:

    • Neurology
    • Immunology
    • Pharmacology

    Context:

    • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Beta-interferon-1b (betaferon) is a disease-modifying therapy used in MS treatment.
    • Understanding treatment efficacy and side effects is crucial for managing MS.

    Purpose:

    • To review the latest clinical data on beta-interferon-1b (betaferon) in various multiple sclerosis (MS) types.
    • To analyze local and systemic side effects associated with betaferon therapy.
    • To evaluate the potential influence of neutralizing antibodies (NAB) on the clinical efficacy of betaferon in MS patients.

    Summary:

    • Beta-interferon-1b (betaferon) demonstrates clinical efficacy across different multiple sclerosis (MS) types.

    Related Experiment Videos

  • Reported side effects are generally moderate and manageable.
  • Current evidence suggests neutralizing antibodies (NAB) do not significantly diminish the positive clinical effects of betaferon.

    • Impact:

    • Betaferon is considered a primary treatment option for multiple sclerosis (MS) due to its manageable side effect profile and sustained efficacy.
    • This review provides valuable insights for clinicians and researchers regarding the long-term use of betaferon in MS.
    • The findings support the continued use of betaferon as a foundational therapy in the management of multiple sclerosis.